Loading company
YD Bio Ltd
YDES · Nasdaq · ·
$7.74+9.7%Sep 29 close
- 1M
- +105.0%
- 6M
- +6.2%
- 1Y
- -56.8%
YDES · Nasdaq · ·
$7.74+9.7%Sep 29 close
From the company’s own 6-K filing.
“2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengthen our balance sheet. Furthermore, we achieved a 17% increase in net revenue, driven predominantly by expanded pharmaceutical sales volumes and strategic new product launches,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. The Company operates DNA methylation–based oncology testing programs in the United States under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. Through strategic partnerships and scalable execution capabilities, the Company aims to advance biomedical innovation with real-world clinical and commercial impact.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K YD Bio Ltd filed on May 1, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
YD Bio Ltd has no earnings call transcript available.